Transcode Therapeutics Stock

Transcode Therapeutics Liabilities

The The Liabilities of Transcode Therapeutics (RNAZ) as of Sep 4, 2026 is 9.31 M USD. In the previous year, The Liabilities was 3.53 M USD — a change of 163.90% (higher).

Liabilities

9.31 MUSD

YoY

163.90%

Last updated:

In 2026, Transcode Therapeutics's total liabilities amounted to 9.31 M USD, a 163.90% difference from the 3.53 M USD total liabilities in the previous year.

The Transcode Therapeutics Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
719,000.00 USD
Jan 1, 2019
1.31 M USD
Jan 1, 2020
4.46 M USD
Jan 1, 2021
2.53 M USD
Jan 1, 2022
4.35 M USD
Jan 1, 2023
3.53 M USD
Jan 1, 2024
9.31 M USD
The Transcode Therapeutics Liabilities history
YEARLiabilitiesYoY
9.31 MUSD+163.90%
3.53 MUSD-18.82%
4.35 MUSD+71.55%
2.53 MUSD-43.23%
4.46 MUSD+239.73%
1.31 MUSD+82.75%
719,000.00USD—
Access this data via the Eulerpool API
Get Free API Key

Transcode Therapeutics Stock analysis

What does Transcode Therapeutics do? Transcode Therapeutics is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Transcode Therapeutics's Liabilities

Transcode Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Transcode Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Transcode Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Transcode Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Transcode Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Transcode Therapeutics stock

The Liabilities of Transcode Therapeutics is 9.31 M USD in 2026.

The Liabilities of Transcode Therapeutics changed from 3.53 M USD to 9.31 M USD, representing a 163.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Transcode Therapeutics since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Transcode Therapeutics historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Transcode Therapeutics

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Transcode Therapeutics